Drug Profile
Research programme: inhibitory small molecule therapeutics - Mitsubishi Tanabe Pharma Corporation
Latest Information Update: 25 May 2010
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 25 May 2010 Discontinued for Undefined indication in Japan (unspecified route)
- 11 Oct 2007 Research in Undefined indication in Japan (unspecified route)